A5048531900- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Eosinophilic Esophagitis
- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Pediatric health and respiratory diseases
- Contact Dermatitis and Allergies
- Respiratory viral infections research
- Transgenic Plants and Applications
- Viral gastroenteritis research and epidemiology
- Polyomavirus and related diseases
- Food Safety and Hygiene
- Drug-Induced Adverse Reactions
- Eosinophilic Disorders and Syndromes
- Child Nutrition and Feeding Issues
- IL-33, ST2, and ILC Pathways
- Information Retrieval and Search Behavior
- Botanical Research and Chemistry
- Plant Virus Research Studies
- Semantic Web and Ontologies
- Peanut Plant Research Studies
- Immune Cell Function and Interaction
- Eating Disorders and Behaviors
- Advanced Text Analysis Techniques
- Library Science and Information Systems
Children's Healthcare of Atlanta
2020-2025
Emory University
2018-2025
Icahn School of Medicine at Mount Sinai
2024
National Institutes of Health
2024
Johns Hopkins University
2024
National Institute of Allergy and Infectious Diseases
2024
Nationwide Children's Hospital
2023
University of North Carolina at Chapel Hill
2012-2019
University of North Carolina Hospitals
2019
Aimmune Therapeutics (United Kingdom)
2017
For egg allergy, dietary avoidance is the only currently approved treatment. We evaluated oral immunotherapy using egg-white powder for treatment of children with allergy.In this double-blind, randomized, placebo-controlled study, 55 children, 5 to 11 years age, allergy received (40 children) or placebo (15). Initial dose-escalation, build-up, and maintenance phases were followed by an food challenge at 10 months 22 months. Children who successfully passed discontinued avoided all...
A unique T helper cell signature in allergic patients isolates the pathogenic cells and provides a target for disease intervention.
Peanut oral immunotherapy, using a variety of approaches, has been previously shown to induce desensitization in peanut-allergic subjects, but no products have approved for clinical use by regulatory agencies.We performed the first phase 2 multicentered study assess safety and efficacy AR101, novel biologic drug product.A randomized, double-blind, placebo-controlled trial was conducted at 8 US centers. Eligible subjects were 4 26 years old, sensitized peanut, had dose-limiting symptoms ≤143...
Food allergies are common and associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy.
Abstract This European Academy of Allergy and Clinical Immunology guideline provides recommendations for diagnosing IgE‐mediated food allergy was developed using the Grading Recommendations, Assessment, Development Evaluations (GRADE) approach. Food diagnosis starts with an allergy‐focused clinical history followed by tests to determine IgE sensitization, such as serum allergen‐specific (sIgE) skin prick test (SPT), basophil activation (BAT), if available. Evidence sensitization should be...
No approved treatment for peanut allergy exists children younger than 4 years of age, and the efficacy safety epicutaneous immunotherapy with a patch in toddlers are unknown. We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving 1 to 3 age confirmed by food challenge. Patients who had an eliciting dose (the necessary elicit allergic reaction) 300 mg or less protein were assigned 2:1 ratio receive delivered means (intervention group) placebo...
BackgroundDespite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There no current agreement about what elements should be included in preparatory or consent process.ObjectiveWe developed consensus recommendations OIT process considerations and patient-specific factors that addressed before initiating a information form.MethodsWe convened 36-member Preparing Patients for Oral Immunotherapy (PPOINT) panel allergy experts...